Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01394471 · ClinicalTrials.gov registry record · Phase 1
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT01394471 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 68 participants.
The verdict
NCT01394471, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, psychotic symptoms and social functioning in schizophrenia. Participants: 80 adults with schizophrenia or schizoaffective disorder for at least one year. Procedures (methods): Oxytocin or placebo will be administered twice daily in an intranasal spray for 12 weeks. Before, during and at the end of the trial, each subject will undergo psychiatric symptom ratings and tests of mental abilities used in social functioning, cognition, and social competence.
Interventions
- DRUG Intranasal Oxytocin Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01394471
The ClinicalTrials.gov registry entry for NCT01394471 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intranasal Oxytocin Spray is the first listed.
NCT01394471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01394471 about?
NCT01394471 is a clinical study titled "Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia". Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, psychotic symptoms and social functioning in schizophrenia. Participants: 80 adults with schizophrenia or schizoaffective disorder for at least one year. Procedures (methods): Oxytocin or plac...
What is the current status of trial NCT01394471?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2011-07. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01394471?
The interventions under investigation include: Intranasal Oxytocin Spray (DRUG).
Who is sponsoring clinical trial NCT01394471?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.